TABLE 3.

Budget and Budget Impact over 3-Year Time Horizon for Treatment of nmCRPC

	Current Market Without Enzalutamide, $	New Market with Enzalutamide, $	Budget Impact, $
nmCRPC regimen	2,043,882	3,356,754	1,312,872
nmCRPC monitoring	11,481	18,029	6,548
nmCRPC adverse events	54,877	55,011	134
nmCRPC visits	320,894	332,068	11,175
mCRPC regimen	3,930,592	3,720,159	–210,433
mCRPC visits	730,796	692,595	–38,201
Aggregate total	7,092,522	8,174,616	1,082,095
PMPM	–	–	0.028

mCRPC = metastatic castration-resistant prostate cancer; nmCRPC = nonmetastatic castration-resistant prostate cancer; PMPM = per member per month.